Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
The chart shows the growth of an initial investment of $10,000 in Lantheus Holdings, Inc, comparing it to the performance of the S&P 500 index. All prices have been adjusted for splits and dividends.
Returns By Period
Lantheus Holdings, Inc (LNTH) has returned 13.92% so far this year and -11.41% over the past 12 months. Looking at the last ten years, LNTH has achieved an annualized return of 44.78%, outperforming the Benchmark (SPY), which averaged 12.23% per year.
LNTH
1M-1.27%
6M41.34%
YTD13.92%
1Y-11.41%
5Y29.67%
10Y44.78%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Lantheus Holdings, Inc (LNTH) with color gradation from worst to best to easily spot seasonal factors.
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2026
0.18%
11.96%
1.70%
-0.41%
2025
3.02%
4.24%
5.27%
6.89%
-28.06%
9.03%
-12.36%
-22.42%
-5.82%
12.90%
2.05%
13.94%
2024
-16.11%
25.13%
-5.05%
7.39%
23.65%
-2.58%
30.47%
1.55%
2.94%
-0.04%
-18.73%
-0.56%
2023
11.76%
28.38%
11.63%
4.09%
1.72%
-3.84%
3.26%
-20.51%
0.56%
-6.47%
11.14%
-13.17%
2022
-12.20%
87.46%
17.68%
19.79%
2.04%
-5.61%
16.61%
2.87%
-9.43%
4.77%
-16.63%
-18.61%
2021
20.43%
11.06%
14.34%
11.01%
2.75%
13.46%
-5.59%
-0.08%
-2.73%
-9.20%
14.59%
5.82%
2020
-15.29%
-8.53%
-17.94%
6.10%
7.18%
3.62%
-5.87%
-0.67%
-4.88%
-14.29%
20.18%
1.28%
2019
9.22%
35.85%
6.34%
-2.46%
-2.44%
18.61%
-21.13%
-3.93%
17.07%
-16.67%
0.92%
-1.87%
2018
11.65%
-33.19%
3.25%
13.02%
-21.35%
2.83%
-0.69%
12.98%
-6.85%
-6.12%
33.93%
-17.63%
2017
-1.73%
49.71%
-4.21%
4.42%
27.20%
6.01%
1.93%
-6.42%
2.01%
11.80%
11.72%
-9.11%
2016
8.99%
-7.14%
88.21%
16.76%
131.07%
-14.90%
5.62%
5.20%
-6.52%
Performance Indicators
The charts below present risk-adjusted performance metrics for Lantheus Holdings, Inc (LNTH) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of LNTH compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Lantheus Holdings, Inc volatility is 3.17%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses. Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Liabilities And Equity (USD)
2.23B
1.98B
1.65B
1.32B
863.78M
869.82M
405.92M
439.83M
383.86M
255.90M
242.38M
Equity Attributable To Parent (USD)
1.09B
1.09B
815.89M
447.15M
464.44M
514.21M
114.60M
71.00M
23.29M
-106.52M
-185.29M
Equity Attributable To Noncontrolling Interest (USD)
Lantheus Holdings reported Q4 2025 revenue of $406.8 million and full-year revenue of $1.54 billion, with adjusted EPS of $1.67 and $6.08 respectively. The company announced a strategic refocus on PET radiodiagnostics and plans to pursue value-maximizing alternatives for radiotherapeutic assets. Despite PYLARIFY sales declining 9.7% in Q4, the company expects up to four FDA approvals in 2026 and provided FY2026 guidance of $1.4-1.45 billion in revenue and $5.00-5.25 adjusted EPS.
GlobeNewswire Inc.•
AI Insight
Mixed results with modest revenue growth (4.0% Q4, 0.5% FY) but declining PYLARIFY sales (-9.7% Q4, -6.5% FY) offset by strategic acquisitions and pipeline expansion. Positive forward guidance and multiple FDA approvals expected in 2026, but the divestiture of legacy SPECT business and shift in strategy suggest operational restructuring. Adjusted EPS growth of 4.7% in Q4 is modest, and full-year adjusted EPS declined from $6.76 to $6.08.
PYLARIFY has become the first blockbuster radiodiagnostic, exceeding $1 billion in 2024 net sales with 24.3% growth. PLUVICTO, a radioligand therapeutic agent, posted $1.392 billion in 2024 sales with 42% growth. PSMA-targeted therapies and radiodiagnostics represent a clinically validated and commercially successful approach for prostate cancer treatment and diagnosis, with multiple radioligands in development.
GlobeNewswire Inc.•Researchandmarkets.Com
AI Insight
PYLARIFY achieved historic milestone as first blockbuster radiodiagnostic with $1.058 billion in 2024 sales and strong 24.3% year-over-year growth, demonstrating robust commercial success and market validation.
Lantheus Holdings announced it will host an earnings conference call and webcast on February 26, 2026, at 8:00 a.m. ET to discuss its fourth quarter and full year 2025 financial and operating results. The company also recently closed the sale of its SPECT business to SHINE Technologies.
GlobeNewswire Inc.•
AI Insight
The article is primarily an announcement of an earnings call and webcast with no forward-looking statements or performance indicators. While the SPECT business sale closure is mentioned, it lacks detail on financial impact or strategic implications, making this a routine corporate announcement without clear positive or negative implications.
Lantheus Holdings has completed the sale of its SPECT diagnostic business to SHINE Technologies, a subsidiary of Illuminated Holdings. The transaction includes diagnostic agents like TechneLite, NEUROLITE, and Cardiolite, along with manufacturing facilities in Massachusetts and Canadian operations. Following the divestiture, Lantheus will focus on its PET radiodiagnostics and microbubbles portfolio.
GlobeNewswire Inc.•
AI Insight
The company successfully completed a strategic divestiture of its SPECT business, allowing it to focus on higher-growth areas like PET radiodiagnostics and microbubbles. This represents a strategic repositioning toward more innovative product lines and demonstrates execution on planned business transformation.
Nitorum Capital fully exited its stake in Lantheus Holdings, selling 344,444 shares worth $28.2 million in Q3. The exit comes as Lantheus faces significant headwinds including a 77% year-over-year earnings decline, declining sales of its flagship prostate cancer imaging agent, CEO retirement, and margin compression despite strong revenue generation.
The Motley Fool•Jonathan Ponciano
AI Insight
GAAP EPS fell 77% year-over-year to $0.41, flagship product sales declined 7.4%, stock down 27% over the past year, facing CEO retirement and portfolio restructuring, rising costs from acquisitions and R&D, and execution risks despite strong cash generation.
Law firm investigating potential securities misconduct for four companies, alleging false statements, misleading financial reporting, and concealment of material facts that impacted stock prices.
GlobeNewswire Inc.•Bragar Eagel & Squire, P.C.
AI Insight
Accused of concealing adverse facts about product competitive positioning and pricing dynamics
Faruqi & Faruqi is investigating potential claims against Lantheus Holdings regarding misleading statements about Pylarify's competitive position, with stock price dropping 28.8% after disappointing Q1 and fiscal year results.
GlobeNewswire Inc.•Faruqi & Faruqi, Llp
AI Insight
Stock price declined 28.8% after reporting below-market Q1 results, reduced growth expectations for Pylarify, and acknowledging competitive challenges impacting pricing dynamics
A class action lawsuit has been filed against Lantheus Holdings for allegedly making false and misleading statements about Pylarify's competitive position and pricing dynamics between November 2024 and August 2025.
GlobeNewswire Inc.•Bragar Eagel & Squire, P.C.
AI Insight
The lawsuit alleges the company concealed material adverse facts about Pylarify's competitive position, misrepresented pricing dynamics, and made misleading statements about business operations and growth potential
Rosen Law Firm is notifying Lantheus Holdings investors of a securities class action lawsuit regarding potential misleading statements about Pylarify's competitive position and pricing dynamics during February 26-August 5, 2025.
GlobeNewswire Inc.•Rosen Law Firm
AI Insight
The lawsuit alleges the company provided false and misleading statements about Pylarify's competitive position, failed to properly disclose pricing risks, and potentially misled investors about the product's growth potential
Rosen Law Firm is notifying Lantheus Holdings investors of a securities class action lawsuit regarding potential misleading statements about Pylarify's competitive position and pricing dynamics during February 26-August 5, 2025.
GlobeNewswire Inc.•Rosen Law Firm
AI Insight
The lawsuit alleges the company provided false and misleading statements about Pylarify's competitive position, failed to properly disclose pricing risks, and potentially misled investors about the product's growth potential
